Media
Genextra press release
-
Jan 25, 2010
Genextra further invests $25 million series B financing in Intercept Pharmaceuticals
(136KB) -
Dec 14, 2009
Genextra S.p.A. raises over € 36 million in equity financing(16,2KB) -
Jul 29, 2008
Genextra completes $25 million financing to support completion of Intercept Pharmaceuticals’ INT-747(30,3KB) -
Sept 28, 2005
Genextra entra nel settore delle nanotecnologie e acquisisce il controllo di Tethis(52KB)
-
Press releases from our companies
-
Jul 6, 2010
Atlante Ventures acquires interest in Tethis (Genextra Group)(136KB) -
Jan 25, 2010
Intercept Pharmaceuticals Raises $25 Million Series B Financing(89,2KB) -
Oct 27, 2009
Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis(16,5KB) -
Oct 2, 2009
Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease(13,9KB) -
Sept 2, 2009
Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity ...(36,0KB) -
Jan 14, 2009
Tethis establishes a collaborative agreement with Cogentech (Consortium for Genomic Technologies, Milan), to validate a novel platform for phosphoproteomic analysis by Mass spectrometry.(71KB) -
Dec 12, 2008
Tethis establishes a collaborative project with European Institute of Oncology, Milan (EIO) to validate its ImmunoCell-Array technology for the analysis of novel putative biomarkers in cancer(70KB) -
Nov 21, 2008
Tethis presents its new system for the deposition of functional coatings on microfabricated devices(55KB) -
Oct 28, 2008
DAC s.r.l. Initiates Phase I/IIa Clinical Trial For DAC-0060 To Treat Nonmelanoma Skin Cancers(51,7KB) -
Aug 7, 2008
Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling, Intercept Pharmaceuticals is Advancing Bile Acid-Derived Small Molecules with Potential Applications in Treating Metabolic Diseases ...(820KB) -
Jul 29, 2008
Intercept Pharmaceuticals Raises $25 Million, Funding Will Support Completion of INT-747 Phase II Clinical Trials and Acceleration of Pipeline Development, Dr. Kenneth D. Noonan Appointed Chairman ...(32,2KB) -
Jan 3, 2008
Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer(35,3KB) -
May 21, 2007
Intercept Pharmaceuticals expands senior management ...(977KB) -
May 16, 2006
Intercept Pharmaceuticals closes $41 million equity financing(16,3KB)